Drug Profile
Research programme: poly(ADP-ribose) polymerase inhibitors - Betta Pharma
Alternative Names: BP715001Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Zhejiang Betta Pharma
- Class
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 07 Jul 2009 Preclinical trials in Cancer in China (unspecified route)